Novavax shares jump as FDA signals path to COVID vaccine approval
Novavax, Inc. (NASDAQ:NVAX) shares surged more than 16% after the company shared a positive update on its COVID-19 vaccine, which it believes is “approvable” based on its conversations with the US Food and Drug Administration (FDA). The company said the FDA has requested additional data on the vaccine as part of a post-marketing commitment (PMC).
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Novavax said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.
Why the Market Dipped But Novavax (NVAX) Gained Today
Novavax (NVAX) closed at $6.01 in the latest trading session, marking a +0.17% move from the prior day.
Here's Why Novavax (NVAX) Fell More Than Broader Market
In the latest trading session, Novavax (NVAX) closed at $6.39, marking a -0.31% move from the previous day.
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CBS News.
2 Beaten-Down Stocks That Still Aren't Worth Buying
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day.
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
